

64th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

602.MYELOID ONCOGENESIS: BASIC

Assesment of Patient'S Perspective on Treatment Free Remission in CML: A Turkish Multicenter Cohort

Yasa gul Mutlu, MD^{1,*}, Birol Guvenc, MD², Istemi Serin, MD^{3,*}, Berrin Balik Aydin, MD^{4,*}, İnci Alacacioğlu, MD^{5,*}, Serkan Guven, MD^{6,*}, Omur Gokmen Sevindik, MD^{7,*}

¹Department of Hematology, Istanbul Medipol University, Izmir, Turkey

²Department of Hematology, Cukurova University, Adana, Turkey

³Department of Hematology, Istanbul Training and Research Hospital, ISTANBUL, TUR

⁴Department of Hematology, Istanbul Medipol University, Istanbul, TUR

⁵Department of Internal Medicine, Division of Hematology, Dokuz Eylül University School of Medicine, İzmir, Turkey

⁶Dokuz Eylul University Hospital, Izmir, TUR

⁷Deaprtment of Hematology, Istanbul Medipol University, Istanbul, TUR

*Asterisk with author names denotes non-ASH members.

Abstract Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' perspective on TFR and factors that associated with willingness for tyrosine kinaz inhibitor (TKI) discontinuation from four different center in Turkey based on a national survey. Patients in our cohort had 7.8% awareness of TFR and after brief information willingness to attempt TFR has been reached to 58.9% in all population. Shorter disease duration was associated with enhanced willingness to attempt discontinuation in multivariate analyses ($p=0.031$). Most common patient related limitation for TKI discontinuation decision was anxiety about disease relaps and TKI resistance. Even disease relaps in TFR means molecular and detectable with close monitoring, patients still had considerable concerns about TKI discontinuation.

Disclosures No relevant conflicts of interest to declare.

<https://doi.org/10.1182/blood-2022-165732>